Plan B Decision May Offer FDA Best Political Protection Available
Executive Summary
Assuming that sexually charged products such as Teva’s emergency contraceptive remain subject to political decision-making, the explicit heavy hand of the HHS secretary in the OTC switch ruling may be the best approach for FDA and the Rx industry, especially considering the alternatives.
You may also be interested in...
A Matter Of Precedent: US FDA Sometimes Labors Under Weight Of Unpopular Or Unfavorable Decisions
As agency observers wonder whether and how political considerations will impact the timing of a COVID-19 vaccine approval or authorization, the Pink Sheet looks at instances through the years where agency staffers found themselves operating under precedents with which they disagreed or that didn’t work out as expected.
FDA Sidelines Chief Spokesperson As It Grapples With Fallout From COVID-19 Plasma Authorization
Emily Miller, who joined FDA a few days before its controversial roll out of emergency use authorization for convalescent plasma, remains at the agency. Situation shows importance of sticking to science-based decisions, former FDA officials say.
Jenkins’ Exit Interview: He’ll Miss Insider Status Upon FDA Departure
Outgoing US FDA Office of New Drugs director tells the Pink Sheet being on the outside will take some adjustment.